I'm surprised no one has posted this from Mr Cox: NanoViricides Turns Away Additional Funding
This is brief, but very important. NanoViricides (OTCBB: NNVC) just announced that the company has ended a relationship with a financial source that would have made significant additional operating funds available to the company in the future. The short press release is here.
What this obtuse financial jargon actually means is that the source of financing will no longer receive stock from the company at a discount, because the company has all the money it needs to get through coming important milestones. At that point, I'm convinced that NanoViricides will have a deal with an established pharmaceuticals company.
Since we are patient investors, we don't panic when a company raises money responsibly, as so many traders do. Raising operating capital is part of the process for startups. In this market, the ability to raise more than enough money is a good sign of the company's health and potential. Nevertheless, the fact that NanoViricides was giving stock to the financing group under market cost resulted in downward pressure on the stock price.
This didn't bother me because I have never felt any need to see short-term gains in NanoViricides' stock price. Instead, I'm counting on enormous transformational profits when the world finally catches on to the fact that this company can cure virtually any virus-borne disease quickly and safely.
Given the cost, inconvenience and irrational fears of vaccines, this is one of the biggest platforms in the history of medicine. It will also have enormous demographic impacts, ending the economic and health damages caused by periodic influenza pandemics, as well as the curses of HIV in Africa, dengue in South America and other tropical killers. Herpes will also be history.
This announcement means, however, that those who have become accustomed to low NanoViricides stock prices may soon see this era come to an end. There will no longer be a constant infusion of underpriced stock to fulfill the appetites of cost averagers.
The company's stock, I believe, would be underpriced even at several multiples of the current price. Nevertheless, the opportunity to get in at historically low cost may be gone soon. As you know, I am prohibited by my arrangement with Agora Financial from owning stock in any company I recommend. NanoViricides is one of a handful of stocks that I want to own so badly that it torments me at night, and this event makes me even more frustrated.
AI
